I welcome all of you to the Wisconsin Rheumatology Association (WRA) 2016 Annual Meeting. We will truly have something of interest for everybody. There will be scientific and clinical sessions given by nationally known experts in rheumatology on such important topics as:

- New rheumatology drugs in the pipeline that will soon be available at a specialty pharmacy near you.
- The latest in progressive systemic sclerosis
- The basic science of rheumatoid arthritis.

We will also have sessions on advocacy at the state and federal levels.

Specifically for our trainees, but appropriate for everybody, Dr. James Dahle will give a session on the crucially important topics of how to plan, develop the best strategies for, and to manage your finances and your investments to insure a healthy financial future all the way through retirement. **Now is the time to start!** We physicians become very good at providing our patients the very best care we can, but many of us have a limited business and investment IQ. I have heard Dr. Dahle give this talk and I am convinced that every medical student, intern, resident and rheumatology fellow needs to attend this session!

To top it off, all of this incredibly good content is at one of Wisconsin’s premiere resorts, the widely renowned American Club in Kohler, Wisconsin. There will be a dinner and other social events, at no extra charge as part of this meeting, with plenty of time for networking with colleagues and industry representatives. Sadly, I cannot promise good golfing weather in early March for 18 holes on Whistling Straights.

Finally, I invite you to join the WRA. Membership is open to all health professionals interested in rheumatology, irrespective of your educational degree. A WRA lifetime membership costs only $75 and there are no annual dues.

Thank you for supporting the WRA by attending the 2016 Annual Meeting.

Best Regards,

Daniel G. Malone, MD, RMSK
President of Wisconsin Rheumatology Association

### WRA 2016 BOARD OF DIRECTORS

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Daniel G. Malone, MD, RMSK</td>
</tr>
<tr>
<td>Vice President</td>
<td>Alvin Wells, MD, PhD</td>
</tr>
<tr>
<td>Secretary/Treasurer</td>
<td>Kurt Oelke, MD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Committee</td>
<td>Daniel G. Malone, MD, RMSK (Chair)</td>
</tr>
<tr>
<td></td>
<td>Kurt Oelke, MD</td>
</tr>
<tr>
<td></td>
<td>Alvin Wells, MD, PhD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Director</td>
<td>Donna Rostamian, MBA</td>
</tr>
</tbody>
</table>
Message from the President .......................................................................................................1
2015 – 2016 WRA Board of Directors ................................................................................1
Needs, Objectives and Accreditation ..................................................................................3
Faculty Disclosure Report .................................................................................................5
Program ................................................................................................................................7
Speaker Biosketches .........................................................................................................9
Industry Support ..............................................................................................................Back Cover

Disclaimer Statement
Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the WRA, nor does the WRA provide any guarantee as to their accuracy or reliability.

Every effort has been made to faithfully reproduce the presentations as submitted. However, no responsibility is assumed by the WRA for any injury and/or damage to persons or property from any cause including negligence or otherwise, or from any use or operation of any methods, products, instruments, or ideas contained in the material herein.

Copyright Notice
Individuals may print out single copies of slides contained in this publication for personal, non-commercial use without obtaining permission from the author or the WRA. Permission from both the WRA and the author must be obtained when making multiple copies for personal or educational use, for reproduction for advertising or promotional purposes, for creating new collective works, for resale or for all other uses.

Filming/Photography Statement
No attendee/visitor at the WRA 2016 Annual Meeting may record, file, tape, photograph, interview or use any other such media during any presentation, display or exhibit without the express, advance approval of the WRA Executive Director. This policy applies to all WRA members, non-members, guests and exhibitors, as well as members of the print, online or broadcast media.
Educational Needs
A better understanding of the pathogenesis and risk factors for SSc is needed in order to develop more effective therapies, as well as accurate diagnosis and classification. Many studies examining genetic risk, molecular pathways and targets are yielding an improved picture of systemic sclerosis and its mechanisms.

Recent trials have yield promising indications for efficacy of selected interventions for SSc. In particular, recent randomized clinical trials have examined immunomodulatory treatments and autologous stem cell therapy in the context of SSc skin and lung disease. Early recognition, accurate risk stratification and targeted intervention are effective in ameliorating symptoms, slowing progression, and improving outcomes for many aspects of SSc.

Biologic agents used in the treatment of rheumatoid arthritis (RA) can result in an increased overall risk of both bacterial and opportunistic infections, malignancy, hyperlipidemia and bone marrow toxicity, among others. Physicians need to be aware of the approved biologic and small molecule medications for the use in RA as well as the required monitoring and precautions when treating RA patients with biologic and small molecule medications.

Physicians, not hospital administrators nor anyone else, should decide what resources will be used for the optimal care of our patients. Physicians need to understand how to use their claims and other resource use data to assure that they can provide the best care to their patients.

How rheumatologists interact with government and private insurance payers becomes more complex and more frustrating daily. Updates on this subject are therefore very important for rheumatologists so they can remain aware of this rapidly changing environment.

Despite their many years of difficult training, most physicians receive little to no training in business, personal finance, and investing. Once you combine that lack of knowledge with the fact that a physician’s high income makes her a target for unscrupulous financial professionals, doctors often make costly financial mistakes. Financial insecurity leads to a difficult work-live balance, decreased work satisfaction, burnout, and even poor patient care. Conversely, developing appropriate financial plans improves each of these aspects.

Educational Objectives
At the conclusion of the WRA 2016 Annual Meeting, attendees should be able to:
1. Explain key genetic studies and their relevance to scleroderma.
2. Describe how cell based and animal model studies might help to identify more effective and targeted therapies for SSc.
3. Explain current approaches to diagnosis and classification of SSc.
4. Employ evidence based approaches to management of SSc.
5. Explain monitoring and precautions when treating RA patients with biologic and small molecule medications.
6. Describe the basic structure of government policies, especially as they pertain to rheumatologic disease.
7. Explain legislative trends regarding practice management and private payer reform of impact to the medical community and rheumatologists throughout the country and related proposals in Wisconsin.
8. Formulate a more thorough understanding of practice management and administrative simplification measures, including uniform prior authorization forms, fair contracting and insurance transparency, and how they will impact practice management and patient care.
9. Identify the most recent legislative updates from the Wisconsin Medical Society, the State and Federal governments.
10. Identify the most expensive components of physician choices in providing patient care.
11. Identify new strategies to avoid insurers trying to micromanage their clinical practice.
12. Recognize the responsibility of insurers to share resource use information with care teams, and realize that working WITH the payers instead of against them is the surest way to minimize overburdening paperwork, denials, prior authorizations etc.
13. Describe several options for dealing with a large student loan burden.
14. Identify how to obtain unbiased financial advice and an appropriate price to pay for it.
CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and the Wisconsin Rheumatology Association. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™
The American College of Surgeons designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

General Disclaimer
The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Wisconsin Rheumatology Association. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Wisconsin Rheumatology Association disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

Special Assistance
We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225, if you require special assistance to fully participate in the meeting.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

ACS is also required, through our joint providership partners, to manage any reported conflict and eliminate the potential for bias during the activity. All program committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

<table>
<thead>
<tr>
<th>PLANNING COMMITTEE/CME ORGANIZERS</th>
<th>DISCLOSURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Company</td>
<td>Role</td>
</tr>
<tr>
<td>MALONE, MD, RMSK, Daniel</td>
<td>AbbVie, Pfizer, Malincrodt</td>
</tr>
<tr>
<td>CME Organizer, Speaker</td>
<td></td>
</tr>
<tr>
<td>OELKE, MD, Kurt</td>
<td>Abbvie, BMS, Amgen, Pfizer, Crescendo Bioscience, UCB</td>
</tr>
<tr>
<td>CME Organizer</td>
<td></td>
</tr>
<tr>
<td>WELLS, MD, PhD, Alvin</td>
<td>Abbvie, Amgen, BMS, Celgene, Genentech, Pfizer, Janssen</td>
</tr>
<tr>
<td>CME Organizer</td>
<td></td>
</tr>
<tr>
<td>SPEAKERS/ MODERATORS/ PANELISTS/ PANELISTS/ DISCUSSANTS/ DISCUSSANTS/ CO-AUTHORS</td>
<td>DISCLOSURE</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td>Company</td>
</tr>
<tr>
<td>BARTHOLOW, MD, Tim Speaker</td>
<td>WEA Trust</td>
</tr>
<tr>
<td>COOPER, Adam Speaker</td>
<td></td>
</tr>
<tr>
<td>CUSH, MD, John Speaker</td>
<td>Pfizer, UCB, Celgene, Amgen, Janssen, Fuji, AbbVie, Novartis</td>
</tr>
<tr>
<td></td>
<td>Janssen, AbbVie, UCB, Pfizer, Novartis, BMS, Amgen, Genentech, Celgene, Ardea, Epirus Biopharmaceuticals</td>
</tr>
<tr>
<td>MALONE, MD, RMSK, Daniel CME Organizer, Speaker</td>
<td>AbbVie, Pfizer, Malincrodt</td>
</tr>
<tr>
<td>OBLUCK, BA, Lori Speaker</td>
<td></td>
</tr>
<tr>
<td>RASCH, Chris Speaker</td>
<td></td>
</tr>
<tr>
<td>VARGA, MD, John Speaker</td>
<td>Roche, Cytori</td>
</tr>
<tr>
<td></td>
<td>Boehringer</td>
</tr>
</tbody>
</table>
WRA PROGRAM

WRA 2016 Annual Meeting
All sessions will be located in Thunder Bay unless otherwise noted
Speakers and times are subject to change

Registration/Information Desk Hours
Location: Great Bay Foyer West
Friday, March 4, 2016 3:00 p.m. – 7:00 p.m.
Saturday, March 5, 2016 7:30 a.m. – 4:00 p.m.

Exhibit Hall Hours
Location: Great Bay Ballroom
Friday, March 4, 2016 5:30 p.m. – 7:00 p.m.
Saturday, March 5, 2016 7:30 a.m. – 1:00 p.m.

FRIDAY, MARCH 4, 2016

3:00 p.m. - 7:00 p.m. Registration/Information Desk Open
Location: Great Bay Foyer

3:30 p.m. - 5:00 p.m. Board of Directors Meeting/Industry Round Table
Location: Marquette Bay

5:30 p.m. - 7:00 p.m. Exhibit Hall Open
Location: Great Bay

SCIENTIFIC SESSION

5:00 p.m. - 5:05 p.m. Opening Remarks
WRA President:
Daniel G. Malone, MD, RMSK
Rheumatology & Musculoskeletal Ultrasound, Beaver Dam Community Hospital Clinic

5:05 p.m. - 6:00 p.m. Keynote Lecture: Novel Approaches to SSc Therapy
John Varga, MD
Northwestern University Medical School

6:00 p.m. - 7:00 p.m. Welcome Reception with Exhibitors
Location: Great Bay

7:30 p.m. - 9:30 p.m. Annual Dinner
Location: Wolf Pack/Bear Clan at Blackwolf Run Clubhouse - Destination Kohler
(The American Club Resort Shuttle available throughout Destination Kohler)

WRA 2016 Annual Meeting
All sessions will be located in Thunder Bay unless otherwise noted
Speakers and times are subject to change

SATURDAY, MARCH 5, 2016

7:30 a.m. - 4:00 p.m.  Registration/Information Desk Open
Location: Great Bay Foyer

7:30 a.m. - 1:00 p.m.  Exhibit Hall Open
Location: Great Bay

7:30 a.m. - 8:30 a.m.  Continental Breakfast in Exhibit Hall

SCIENTIFIC SESSION

8:30 a.m. - 8:35 a.m.  Opening Remarks

8:35 a.m. - 9:30 a.m.  Progress in Understanding Systemic Sclerosis
John Varga, MD
Northwestern University Medical School

9:30 a.m. - 10:30 a.m.  Advances in RA Therapy
John J. Cush, MD
Baylor Research Institute

10:30 a.m. - 11:00 a.m.  Beverage Break and Networking Session in Exhibit Hall

11:00 a.m. - 12:00 p.m.  *Pearls in Personal Finance & Investing
James M. Dahle, MD FACEP
The White Coat Investor, LLC
*NOT CME Accredited

12:00 p.m. - 1:00 p.m.  Networking Lunch in Exhibit Hall

1:00 p.m. - 2:00 p.m.  Insurance Issues/Advocacy
Timothy Bartholow, MD
WEA Trust Insurance Company

2:00 p.m. - 2:15 p.m.  Beverage Break

2:45 p.m. - 3:15 p.m.  Annual Business Meeting

3:15 p.m. - 4:00 p.m.  State & Federal Advocacy Updates

3:15 p.m. - 3:30 p.m.  Arthritis Foundation Update
Lori Obluck, BA
Arthritis Foundation

3:30 p.m. - 3:45 p.m.  ACR Advocacy Update
Adam Cooper
American College of Rheumatology

3:45 p.m. - 4:00 p.m.  Wisconsin Medical Society State Advocacy Update
Chris M. Rasch
Wisconsin Medical Society
Timothy Bartholow, MD
Dr. Bartholow is the VP and first Chief Medical Officer at WEA Trust. Before joining the Trust, Dr. Bartholow served as the Wisconsin Medical Society’s Chief Medical Officer for five years. In this role, he focused on physician and community engagement to promote change in the delivery and payment of health care. Prior to joining the society staff in November 2008, Dr. Bartholow spent 16 years caring for patients at the Prairie Clinic in Sauk City, Wisconsin, where he was one of 12 clinical owners and on EMR since 2003. He believes that organized and carefully articulated physician feedback is essential for systems to serve the goal of best care. In the late 1990s, he served as medical director for an independent physician association with two-sided risk with more than 400 primary care providers, a precursor to ACOs.

Adam Cooper
Mr. Cooper serves as Senior Director of Government Affairs for the American College of Rheumatology. The ACR represents over 9,500 rheumatologists and rheumatology health professionals in the United States and across the world. As a leading advocate for rheumatology, the ACR works with decision makers in Washington, D.C. and in states around the nation to improve policy outcomes. The ACR's advocacy focuses on improving access to rheumatologists and rheumatologic care, improving the practice climate for rheumatologists, enhancing patient access to treatments, and increasing funding for medical research. RheumPAC, the ACR's non-partisan political action committee, helps support and elect pro-rheumatology candidates to Congress.

In his current role, Adam guides the ACR's legislative and regulatory engagement and its implementation of public policy and advocacy programs. Prior to his work at the ACR, Adam served as a vice president at an Atlanta-based public affairs firm, managing the state and federal government relations needs of corporate clients, and as manager of government affairs for the Asheville Area Chamber of Commerce in Asheville, North Carolina. Adam received his BS in political science from Presbyterian College in Clinton, South Carolina, and his Master's degree in political science from Emory University in Atlanta, Georgia.

John J. Cush, MD
Dr. Cush is the director of clinical rheumatology at the Baylor Research Institute, and professor of medicine and rheumatology at Baylor University Medical Center in Dallas, Texas. Dr. Cush received his medical degree from St. George's University School of Medicine in Grenada, West Indies. He completed his rheumatology training at The University of Texas Health Science Center and Parkland Memorial Hospital in Dallas. Dr. Cush's areas of clinical research include diagnostics, disease management, and therapeutic treatment. His extensive research in the field of rheumatology is chronicled in over 140 journal articles.


He has served on the Arthritis Advisory Committee for the Food and Drug Administration, held numerous leadership positions for the American College of Rheumatology, editorial positions for the Journal of Rheumatology, Seminars in Arthritis & Rheumatism and is past editor of the ACR's Hotline and Drug Safety Quarterly.

He is the executive editor of *RheumNow.com* - a news, information and education website dedicated to rheumatologists.
James M. Dahle, MD FACEP
Dr. Dahle graduated from Brigham Young University with a BS in molecular biology in 1999 and the University of Utah School of Medicine in 2003. He trained at the University of Arizona Emergency Medicine Residency Program from 2003-2006, and then served four years with the Air Force and the Navy, practicing medicine on four different continents. He is now a partner and the department chair with Utah Emergency Specialists, working full-time in a community hospital in the Salt Lake Valley.

In residency, he developed an interest in personal finance and investing. In 2011, he started The White Coat Investor, now the most widely-read physician-specific personal finance and investing website in the world with over 350,000 page-views per month. In February 2014, he published *The White Coat Investor, A Doctor's Guide to Personal Finance and Investing*, which has remained #1 or # 2 in its category on Amazon since publication. His financial articles have appeared in numerous online and printed publications and he is a sought-after speaker best known for helping physicians and other high-income professionals get a "fair shake" on Wall Street.

Daniel G. Malone, MD, RMSK
Dr. Malone started his college education at Cornell University in Ithaca, New York, earning a Bachelor of Arts in Physics and later earning his Medical Degree from the University of Illinois, Abraham Lincoln School of Medicine, Chicago, Illinois, in 1976. He is currently the Clinical Associate Professor of Medicine—Rheumatology, Medical College of Wisconsin in Milwaukee, Wisconsin.

In addition to being the President and member of the Wisconsin Rheumatology Association, he is also a member of the American College of Rheumatology, the American Institute for Ultrasound in Medicine, the International Society for Clinical Densitometry and the American Registry of Diagnostic Medical Sonographers.

Dr. Malone currently lives in Madison, Wisconsin, with his wife, Ann Elizabeth Malone, and four children.

Lori Obluck, BA
Ms. Obluck is the regional director of advocacy and public policy at the Arthritis Foundation, where she has worked since 2006. Before working at the Arthritis Foundation, Ms. Obluck served as a patient service director at the American Cancer Society for 13 years. Her previous experience also includes working with the Children’s Service Society of Wisconsin and the American Red Cross. She earned her BA in social work from the University of Wisconsin-Whitewater in 1977.

Kurt Oelke, MD
Dr. Kurt Oelke, a rheumatologist with the Rheumatic Disease Center in Glendale, Wisconsin, has dedicated much of his career to studying and treating rheumatic diseases. In 1997 Dr. Oelke received his MD from the University of Wisconsin – Madison. In 2000, after finishing his residency at Vanderbilt University Medical Center in Nashville, Tennessee, Dr. Oelke went on to complete a fellowship with the University of Michigan Department of Rheumatology in Ann Arbor two years later. He was a junior faculty member at the University of Michigan prior to moving to Milwaukee, Wisconsin, where he served as the president of the Wisconsin Rheumatology Association for two years. Since 2004, he has been the clinical research director at the Rheumatic Disease Center.

Dr. Oelke has contributed to several publications including *Arthritis and Rheumatism*, *International Reviews of Immunology*, and *Investigational Drugs Journal*. In addition, Dr. Oelke has been the principal investigator of over 15 clinical trials assessing the efficacy of various treatments for rheumatic conditions and frequently lectures to physicians on rheumatic disease treatment.
THANK YOU TO OUR 2016
PROMOTIONAL PARTNERS
(as of 2/18/2016)

**Gold Level**
Abbvie

**Silver Level**
Alexion Pharmaceuticals
Amgen
Janssen Biotech, Inc.

---

THANK YOU TO OUR 2016
EXHIBITORS
(as of 2/18/2016)

Abbvie
Amgen, Inc.
Antares Pharma
Celgene Corporation
Crescendo Bioscience, Inc.
Genentech
Gilead Sciences, Inc.
GlaxoSmithKline
Horizon Pharma, Inc.
Janssen Biotech, Inc.
Lilly
Mallinckrodt Pharmaceuticals
Medac Pharma, Inc.
Pfizer, Inc.
Purdue Pharma L.P.
Sobi, Inc.